Abbott Laboratories v. Super. Ct.

CourtCalifornia Court of Appeal
DecidedMay 31, 2018
DocketD072577
StatusPublished

This text of Abbott Laboratories v. Super. Ct. (Abbott Laboratories v. Super. Ct.) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Abbott Laboratories v. Super. Ct., (Cal. Ct. App. 2018).

Opinion

Filed 5/31/18 CERTIFIED FOR PUBLICATION

COURT OF APPEAL, FOURTH APPELLATE DISTRICT

DIVISION ONE

STATE OF CALIFORNIA

ABBOTT LABORATORIES et al.,

Petitioners,

v. D072577 THE SUPERIOR COURT OF ORANGE COUNTY, (Orange County Super. Ct. No. 30-2016-00879117-CU-BT-CXC) Respondent;

THE PEOPLE ex rel. TONY RACKAUCKAS, as District Attorney, etc.,

Real Party in Interest.

ORIGINAL PROCEEDINGS in mandate following denial of a motion to strike

under Code of Civil Procedure sections 435 and 436, Kim G. Dunning, Judge. Petition

granted.

Kirkland & Ellis and Michael John Shipley, Jay P. Lefkowitz, Adam T. Humann

and Yosef Mahmood for Petitioners Teva Pharmaceuticals USA, Inc., Duramed

Pharmaceuticals Sales Corp., Inc. and Barr Pharmaceuticals, Inc. Munger, Tolles & Olson and Jeffrey I. Weinberger, Stuart N. Senator and Blanca

F. Young for Petitioners AbbVie Inc. and Abbott Laboratories.

Horvitz & Levy and Jeremy Brooks Rosen, Stanley H. Chen, Janet Y. Galeria, for

Chamber of Commerce of the United States of America; Heather Lynn Wallace, for

California Chamber of Commerce as Amici Curiae on behalf of Petitioners.

Tony Rackauckas, Orange County District Attorney, Joseph D'Agostino, Assistant

District Attorney, Kelly A. Ernby, Deputy District Attorney; Robinson Calcagnie Inc. and

Mark P. Robinson, Jr., Kevin F. Calcagnie on behalf of Real Party in Interest.

Dennis J. Herrera, City Attorney, Yvonne R. Mere, Owen J. Clements, Deputy

City Attorneys, for the City and County of San Francisco; Michael Feuer, City Attorney,

Monica D. Castillo, Deputy City Attorney, for the City of Los Angeles; Mara W. Elliot,

City Attorney, Kathryn Turner, Kristine Lorenz, Deputy City Attorneys for the City of

San Diego; Richard Doyle, City Attorney, Nora Frimann, Assistant City Attorney for the

City of San Jose; James R. Williams, County Counsel, Greta S. Hansen, Danny Chou,

Assistants County Counsel, Laura S. Trice, Deputy County Counsel, for Santa Clara

County; Jennifer Henning for California State Association of Counties as Amici Curiae

on behalf of Real Party in Interest.

Law Office of Valerie T. McGinty and Valerie T. McGinty for Consumer

Attorneys of California as Amicus Curiae on behalf of Real Party in Interest.

Xavier Becerra, Attorney General, Nicklas A. Akers, Assistant Attorney General,

Michele R. Van Gelderen, Daniel A. Olivas and David A. Jones, Deputy Attorneys

General for California Attorney General as Amicus Curiae.

2 Mark Louis Zahner of the California District Attorneys Association and Thomas

Atlee Papageorge of the San Diego District Attorney's Office, for the California District

Attorneys Association as Amici Curiae.

The Orange County District Attorney (the District Attorney), representing "the

People of the State of California," sued petitioners Abbott Laboratories, AbbVie Inc.,

Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals, Inc., Duramed Pharmaceuticals,

Inc. and Duramed Pharmaceuticals Sales Corp., alleging generally that petitioners

engaged in a scheme to keep generic versions of a prescription drug off the market in

violation of California's Unfair Competition Law (UCL; Bus. & Prof. Code,1 § 17200 et

seq.). The District Attorney sought an injunction as well as civil penalties and restitution.

Petitioners unsuccessfully moved to strike portions of the operative complaint alleging

"claims for restitution and civil penalties based on conduct outside the territorial

jurisdiction of Orange County."

In this writ proceeding, petitioners ask us to resolve a single issue: whether section

17204 of the UCL "permit[s] a county district attorney to bring a claim that seeks relief

for alleged injuries to residents of California counties whom he or she does not represent,

based on conduct occurring outside the county he or she serves . . . ." Petitioners argue

district attorneys have no authority to prosecute civil actions absent specific legislative

authorization, and neither the Government Code, nor Business and Professions Code

1 Statutory references are to the Business and Professions Code unless otherwise specified. 3 section 17204, authorize the district attorney of a single county to seek statewide

penalties for alleged UCL violations. The California Attorney General has filed an

amicus brief on the question, as have the California District Attorneys Association; the

City Attorneys of Los Angeles, San Diego, San Francisco, and San Jose, Santa Clara

County Counsel, and California State Association of Counties (collectively the city

attorneys); the United States and California Chambers of Commerce (collectively

Chambers of Commerce); and the Consumer Attorneys of California.

We grant the petition. The California Constitution designates the Attorney

General the "chief law officer of the State" (Cal. Const., art. V, § 13), and consistent with

this constitutional provision, the Attorney General "has charge, as attorney, of all legal

matters in which the State is interested" (Gov. Code, § 12511) and also "shall . . .

prosecute or defend all causes to which the State . . . is a party in his or her official

capacity." (Gov. Code, § 12512.) The District Attorney, on the other hand, is a county

officer whose territorial jurisdiction and power is limited accordingly. Though section

17204 confers standing on district attorneys to sue in the name of the people of the State

of California, it cannot constitutionally or reasonably be interpreted to grant the District

Attorney power to seek and recover restitution and civil penalty relief for violations

occurring outside the jurisdiction of the county in which he was elected. A contrary

conclusion would permit the District Attorney to usurp the Attorney General's statewide

authority and impermissibly bind his sister district attorneys, precluding them from

pursuing their own relief. Thus, in the absence of written consent by the Attorney

4 General and other county district attorneys, the District Attorney must confine such

monetary recovery to violations occurring within the county he serves.

FACTUAL AND PROCEDURAL BACKGROUND

Petitioners are companies or wholly-owned subsidiaries involved in the

manufacture, distribution or sale of pharmaceuticals or generic prescription drugs,

including the prescription drug Niaspan. In October 2016, the Orange County District

Attorney, representing "the People of the State of California" in association with private

counsel, filed a complaint for violations of the UCL, alleging that petitioners either

entered into agreements or otherwise engaged in conduct that prevented other generic

manufacturers from launching their own Niaspan equivalent, causing purchasers and

others in California to overpay for the drug. The District Attorney filed a first amended

complaint, the operative pleading, in December 2016. In part, the operative complaint

alleges that "[e]ach sale of Niaspan in violation of Section 17200 constitutes a separate

violation," and purchasers in California sustained substantial losses in the form of

overcharges on each sale based on the petitioners' unlawful and unfair business practices,

which violated federal, state, and/or common laws, including federal and state antitrust

laws. It alleges that "the violations of California law complained of herein resulted in

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Aryeh v. Canon Business Solutions, Inc.
292 P.3d 871 (California Supreme Court, 2013)
Vandermost v. Bowen
269 P.3d 446 (California Supreme Court, 2012)
Sullivan v. Oracle Corp.
254 P.3d 237 (California Supreme Court, 2011)
Zhang v. Superior Court
304 P.3d 163 (California Supreme Court, 2013)
Candid Enterprises, Inc. v. Grossmont Union High School District
705 P.2d 876 (California Supreme Court, 1985)
Woodland Hills Residents Ass'n v. City Council of Los Angeles
593 P.2d 200 (California Supreme Court, 1979)
People v. Superior Court
507 P.2d 1400 (California Supreme Court, 1973)
Babb v. Superior Court
479 P.2d 379 (California Supreme Court, 1971)
Cortez v. Purolator Air Filtration Products Co.
999 P.2d 706 (California Supreme Court, 2000)
Kraus v. Trinity Management Services, Inc.
999 P.2d 718 (California Supreme Court, 2000)
City of Oakland v. Brock
67 P.2d 344 (California Supreme Court, 1937)
Robbins v. Superior Court
695 P.2d 695 (California Supreme Court, 1985)
Burden v. Snowden
828 P.2d 672 (California Supreme Court, 1992)
D'AMICO v. Board of Medical Examiners
520 P.2d 10 (California Supreme Court, 1974)
Pitts v. County of Kern
949 P.2d 920 (California Supreme Court, 1998)
Taylor v. Superior Court
598 P.2d 854 (California Supreme Court, 1979)
Collins v. Riley
152 P.2d 169 (California Supreme Court, 1944)
People v. Pacific Land Research Co.
569 P.2d 125 (California Supreme Court, 1977)
Avco Community Developers, Inc. v. South Coast Regional Commission
553 P.2d 546 (California Supreme Court, 1976)

Cite This Page — Counsel Stack

Bluebook (online)
Abbott Laboratories v. Super. Ct., Counsel Stack Legal Research, https://law.counselstack.com/opinion/abbott-laboratories-v-super-ct-calctapp-2018.